Obesity Management

Community pharmacists weave brief lifestyle coaching and point-of-care testing into medication management, improving diabetes and hypertension outcomes.

Emily Eddy, PharmD, BCACP, BC-ADM, CDCES, presents on the ever-expanding world of glucagon-like peptide-1s, now heading toward indications for chronic kidney disease and substance use disorder.

With a slew of new GLP-1 indications approved in recent history, researchers and experts are now diving into their use in treating substance use disorders.

Pharmacists boost chronic disease outcomes by adding quick nutrition screening, counseling, and drug-nutrient checks to everyday visits.

Orforglipron is the first new molecular entity to be cleared under the FDA Commissioner's National Priority Voucher pilot program.

The FDA clears the highest-dose weekly semaglutide for obesity, showing 20.7% mean weight loss with the same blood sugar-lowering effects.

With ongoing concerns about the safety and formulation of compounded GLP-1s, Annie Lambert, PharmD, BCSCP, added her expert insights into the recent crackdown of these products.

Annie Lambert, PharmD, BCSCP, discusses pharmacies’ regulation and compliance needs when it comes to dispensing compounded GLP-1s.

The health care landscape for metabolic liver disease is undergoing a shift, and pharmacists are being positioned at the forefront of this therapeutic revolution.

Annie Lambert, PharmD, BCSCP, discusses the key approaches to ensuring safe and effective dispensing of compounded GLP-1 medications.

Eli Lilly flags unknown impurities in compounded tirzepatide with B12 as FDA targets misleading GLP-1 marketing.

Previously, bimagrumab monotherapy in adults with type 2 diabetes led to a 20.5% reduction in total body fat mass and a 0.76 percentage point decrease in hemoglobin A1c.

Once weekly petrelintide, a long-acting amylin analog, delivers up to 10.7% weight loss with placebo-like gastrointestinal tolerability in phase 2.

FDA targets telehealth ads for compounded glucagon-like peptide-1s, warning of misleading claims, hidden sources, and safety risks amid social media hype.

Orforglipron beats oral semaglutide in A1C and weight loss in a head-to-head study for type 2 diabetes.

Navitus Health Solutions conducted a survey of 2000 US adults who have been taking glucagon-like peptide-1 therapies for the past 2 years.

Novo Nordisk’s CagriSema drives 23% weight loss in REDEFINE 4 but misses noninferiority compared with tirzepatide, shaping the next wave of obesity drugs.

With expanding scopes of practice, there has never been a better time to introduce or expand clinical services that improve patient outcomes.

Buchanan Ingersoll & Rooney’s Dae Lee, PharmD, Esq, CPBS, and Lucas Morgan, Esq, provide a timely legal update regarding GLP-1 distribution and compounding.

Pfizer's phase 2b study reveals promising results for its monthly GLP-1 therapy, enhancing weight loss and medication adherence in obesity management.

Novo Nordisk's CagriSema shows significant improvements in blood glucose control and weight loss for type 2 diabetes patients in recent trial results.

GLP-1 therapies gain popularity, but patient adherence struggles due to fragmented support and emotional barriers.

The company announces that the pill is now available at over 70,000 pharmacies across the country.

Orforglipron shows promise in maintaining weight loss for those transitioning from injectable GLP-1 therapies, offering a convenient oral alternative.

With brand-new challenges and opportunities in the GLP-1 space and obesity management as a whole, here are the top developments from the past year.